Pacific Edge reviews US pricing for new Cxbladder test, trading halted

Pacific Edge reviews US pricing for new Cxbladder test, trading halted
Pacific Edge says Cxbladder Triage Plus delivers “significant performance improvements” compared to its existing tests. (Image: Pacific Edge)
Rebecca Howard
Pacific Edge has been placed on a trade halt while it reviews draft gapfill or reimbursement rates for its new Cxbladder Triage Plus test from the US Centres for Medicare and Medicaid Services.“[It said it's] reviewing the prices and the associated documentation and needs time to assess the implications of them, consult with its advisers and industry partners, and prepare an announcement that provides context to investors.”Gapfill prices are proposed reimbursement rates for new or unpriced clinical diagnostic laboratory tests.Th...

More Markets

Flick not profitable before $70m sale to Meridian
Markets

Flick not profitable before $70m sale to Meridian

After eight years of trying in electricity retailing, Z throws in the towel.

The cheese deal with Fonterra that 'really kick-started' Bega
Primary Sector

The cheese deal with Fonterra that 'really kick-started' Bega

The owner of Vegemite now wants to get its hands on Fonterra’s brands.

US-China détente hopes send Mainfreight up 5%
Markets Market Close

US-China détente hopes send Mainfreight up 5%

Harbour Asset Management's Shane Solly says good signs are coming out of Geneva.

Gregor Thompson 12 May 2025